利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

101 条记录 (耗时 0.023 秒)

    Antacid and laxative tablets
    1.
    发明申请
    Antacid and laxative tablets 失效
    抗酸泻药片

    公开(公告)号：US20040022872A1

    公开(公告)日：2004-02-05

    申请号：US10380407

    申请日：2003-06-10

    发明人： Mitsuhiro Sofue ,  Isamu Kawamura ,  Shigeo Yamao ,  Hideaki Baba ,  Shiro Horie ,  Yoko Abe ,  Hisae Sofue

    IPC分类号： A61K033/08 ,  A61K031/716 ,  A61K031/717

    CPC分类号： A61K33/08 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059

    摘要： An antacid and laxative tablet comprising magnesium oxide particles as an effective component, wherein (i) the magnesium oxide particles contained in the tablet have an average secondary particle diameter measured by a laser diffraction scattering method of 0.5 to 10 nullm, (ii) the content of magnesium oxide particles in the tablet is 88 wt % or more, (iii) the tablet does not become blackish and has substantially no tableting spot, and (iv) the disintegration time is 10 sec or less. The antacid and laxative tablet of the present invention has a high content of magnesium oxide particles, a short disintegration time, does not become blackish, has no tablet trouble and no tableting spot and is suitably administered orally.

    摘要翻译： 一种含有氧化镁粒子作为有效成分的抗酸泻药片，其中，（i）片剂中含有的氧化镁粒子的平均二次粒径通过激光衍射散射法测定为0.5〜10μm，（ii）含量 片剂中的氧化镁颗粒为88重量％以上，（iii）片剂不变黑，基本上不具有压片斑，（iv）崩解时间为10秒以下。 本发明的抗酸泻药片具有高含量的氧化镁颗粒，崩解时间短，不变黑，没有片剂麻烦，没有压片斑点，适合口服施用。

    Extended release formulation
    4.
    发明申请
    Extended release formulation 审中-公开

    公开(公告)号：US20030215507A1

    公开(公告)日：2003-11-20

    申请号：US10413076

    申请日：2003-04-14

    申请人： Wyeth

    发明人： Deborah M. Sherman ,  John C. Clark ,  John U. Lamer ,  Steven A. White

    IPC分类号： A61K031/277 ,  A61K009/14 ,  A61K009/22 ,  A61K031/717

    CPC分类号： A61K9/1652 ,  A61K9/5047 ,  A61K31/137

    摘要： This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

    Compositions for treating hyperemia
    7.
    发明申请
    Compositions for treating hyperemia 有权
    用于治疗充血的组合物

    公开(公告)号：US20030203034A1

    公开(公告)日：2003-10-30

    申请号：US10133094

    申请日：2002-04-26

    申请人： Allergan Sales, Inc.

    发明人： Stanley W. Huth

    IPC分类号： A61K031/717 ,  A61K031/137 ,  A61K033/14 ,  A61K009/14

    CPC分类号： A61K31/137 ,  A61K9/0048 ,  A61K31/717 ,  A61K47/38

    摘要： The present compositions advantageously treat hyperemia with substantially no added irritation to the eye. In one embodiment, the compositions include an ophthalmically acceptable carrier component, a vasoconstrictor component in an amount effective to treat hyperemia when the composition is administered to an eye, and a polyanionic component in an amount effective to provide lubrication to an eye when the compositions are administered to the eye.

    摘要翻译： 本发明组合物有利地治疗充血，基本上没有刺激眼睛。 在一个实施方案中，组合物包括眼用可接受的载体组分，当将组合物施用于眼睛时有效治疗充血的量的血管收缩剂组分，以及当组合物为眼睛时有效提供眼睛润滑的量的聚阴离子组分 给予眼睛。

    Anti-adhesion barrier
    10.
    发明申请
    Anti-adhesion barrier 审中-公开
    防粘连屏障

    公开(公告)号：US20030124087A1

    公开(公告)日：2003-07-03

    申请号：US10316853

    申请日：2002-12-12

    申请人： Amitie Co. Ltd.

    发明人： Dae Sik Kim ,  Do Hoon Kim ,  Jeong Kwon Lee

    IPC分类号： A61K031/74 ,  A61K031/727 ,  A61K031/717 ,  A61K038/20 ,  A61K031/56 ,  A61K031/198

    CPC分类号： A61L31/041 ,  C08L5/00 ,  C08L1/28

    摘要： The present invention relates to anti-adhesion barriers which prevents an adhesion between tissues at an operated legion and have various shapes, comprising sodium carboxymethyl cellulose (NaCMC) and gellan gum in 1:(0.1null10) of weight ratio. The anti-adhesion barriers of the present invention prevent adhesions at the operated legion or between bleeding legion and existed tissues more effectively after self-transplantation and being sealed completely, than conventional anti-adhesion barriers do and moreover, have remarkable haemostatic effects, anti-inflammation adhesion and application effect.

    摘要翻译： 本发明涉及一种防粘连屏障，其防止在操作的军团上的组织之间的粘附并具有各种形状，其包含羧甲基纤维素钠（NaCMC）和结晶胶，其重量比为1：（0.1〜10）。 本发明的防粘附屏障比常规抗粘连屏障更能有效地防止自体移植后完全密封下的运动军团，出血军团和存在的组织之间的粘连，此外具有显着的止血作用， 炎症粘连和应用效果。